Compare · QNRX vs SYK
QNRX vs SYK
Side-by-side comparison of Quoin Pharmaceuticals Ltd. (QNRX) and Stryker Corporation (SYK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QNRX and SYK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- SYK is the larger of the two at $121.75B, about 9311.5x QNRX ($13.1M).
- Over the past year, QNRX is down 8.9% and SYK is down 18.6% - QNRX leads by 9.7 points.
- Both names hit the wire about 7 times in the past 4 weeks.
- SYK has more recent analyst coverage (25 ratings vs 0 for QNRX).
- Company
- Quoin Pharmaceuticals Ltd.
- Stryker Corporation
- Price
- $6.54+2.75%
- $317.36-1.99%
- Market cap
- $13.1M
- $121.75B
- 1M return
- +45.98%
- -6.97%
- 1Y return
- -8.91%
- -18.61%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2016
- News (4w)
- 7
- 7
- Recent ratings
- 0
- 25
Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals, Ltd., a specialty pharmaceutical company, focuses on the development of therapeutic products for rare and orphan diseases. The company's lead product is QRX003, a topical lotion to treat Netherton Syndrome. It also develops QRX004 for the treatment dystrophic epidermolysis bullosa; and QRX006, a therapy to treat rare skin disease. The company is based in Ashburn, Virginia.
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. The Neurotechnology and Spine segment provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; and minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
Latest QNRX
- Director Langer Dennis was granted 34,534 units of ADSs, increasing direct ownership by 159% to 56,243 units (SEC Form 4)
- Director Culverwell Anthony James was granted 31,352 units of ADSs, increasing direct ownership by 1,094% to 34,218 units (SEC Form 4)
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Quoin Pharmaceuticals Reports Positive Interim Data from Ongoing Phase 2/3 Study of QRX003 in Netherton Syndrome
- Quoin Pharmaceuticals Announces Private Placement Financing of Up to $50.0 Million
- Quoin Pharmaceuticals Ltd. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Other Events
- Quoin Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2026 Financial Results
- Quoin Pharmaceuticals to Announce Corporate Update and Second Quarter 2026 Financial Results on Friday, August 14, 2026
- SEC Form DEF 14A filed by Quoin Pharmaceuticals Ltd.
- Quoin Pharmaceuticals Receives FDA IND Clearance to Initiate Phase 2 Study of QRX003 in Peeling Skin Syndrome
Latest SYK
- Stryker introduces first of its kind FDA-authorized surgical application for Apple Vision Pro with hip arthroscopy case at nationally recognized academic medical center
- Stryker signs definitive agreement to acquire ZuriMED to enhance its shoulder offering
- Stryker to participate in the 2026 Wells Fargo Healthcare Conference
- Group President Crotty Dylan Bram sold $144,915 worth of shares (441 units at $328.61) (SEC Form 4)
- Director Stryker Ronda E sold $117,776,128 worth of shares (350,000 units at $336.50) (SEC Form 4)
- Officer King Debra sold $277,787 worth of shares (826 units at $336.30), decreasing direct ownership by 12% to 6,210 units (SEC Form 4)
- Stryker downgraded by Wolfe Research
- Providence™ Medical Technology Appoints Lane Major as President & Chief Executive Officer
- Stryker declares an $0.88 per share quarterly dividend
- VP, Chief Comm. Officer Montagnino Kimberly Ann covered exercise/tax liability with 155 shares, decreasing direct ownership by 8% to 1,717 units (SEC Form 4)